This clinical study made use of an ‘active drug’ PK assay measuring the concentration of drug able to bind both TYRP1 and CD3 proteins simultaneously, and therefore capable of promoting synapse formation between TYRP1-expressing melanoma cells and CD3+ T cells. The gene discussed is TYRP1; the disease is melanoma.